Nippon Shinyaku Co Ltd (NPPNY)
7.71
0.00 (0.00%)
USD |
OTCM |
Apr 18, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.077B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -31.10% |
| Valuation | |
| PE Ratio | 12.27 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.983 |
| Price to Book Value | 1.362 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.1053 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 66.23% |
Profile
| Nippon Shinyaku Co Ltd is a specialty and generic drug manufacturing company. Nippon's research and development activities include a focus on pharmaceuticals, nutraceuticals, safety and pharmacokinetics of drug seeds, genomic drug discovery, and nucleic acid drugs. The company also develops health food ingredients, preservatives, protein preparations, and spices. Nippon considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. |
| URL | http://www.nippon-shinyaku.co.jp |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 28, 2023 |
Ratings
Profile
| Nippon Shinyaku Co Ltd is a specialty and generic drug manufacturing company. Nippon's research and development activities include a focus on pharmaceuticals, nutraceuticals, safety and pharmacokinetics of drug seeds, genomic drug discovery, and nucleic acid drugs. The company also develops health food ingredients, preservatives, protein preparations, and spices. Nippon considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. |
| URL | http://www.nippon-shinyaku.co.jp |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 28, 2023 |